Temozolomide (TMZ) and cisplatin (CDDP) combination in naive patients with stage IV melanoma. Definitive results of a phase II multicenter trial

被引：0
|
作者：
Tourani, J.
Wiersbicka, E.
Mourey, L.
Guillot, B.
Sassolas, B.
Bedane, C.
机构：
[1] CHU Poitiers, Poitiers, France
[2] Inst Claudius Regaud, Toulouse, France
[3] CHU Montpellier, Hop St Eloi, Montpellier, France
[4] CHU Brest, Brest, France
[5] CHU Limoges, Limoges, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8572
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Temozolomide and cisplatin combination in naive patients with metastatic cutaneous melanoma: results of a phase II multicenter trial
    Wierzbicka-Hainaut, Ewa
    Sassolas, Bruno
    Mourey, Laurent
    Guillot, Bernard
    Bedane, Christophe
    Guillet, Gerard
    Tourani, Jean Marc
    MELANOMA RESEARCH, 2010, 20 (02) : 141 - 146
  • [2] Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma.
    Cunningham, C.
    Pavlick, A. C.
    Khan, K. D.
    Frenette, G.
    O'Day, S.
    Stephenson, J.
    Gonzalez, R.
    Yang, Z.
    Vrhovac, V.
    Uprichard, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 462S - 462S
  • [3] Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial
    Tas, F
    Argon, A
    Camlica, H
    Topuz, E
    MELANOMA RESEARCH, 2005, 15 (06) : 543 - 548
  • [4] Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HOB) IL-2 in patients with AJCC stage IV melanoma.
    Tarhini, A
    Agarwala, SS
    Gooding, W
    Cai, C
    Kirkwood, JM
    Stover, LL
    Blair, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 722S - 722S
  • [5] Temozolomide (TMZ) plus thalidomide (THAL) as adjuvant therapy in patients with stage III and stage IV malignant melanoma.
    Hwu, WJ
    Coit, D
    Jaques, D
    Panageas, KS
    Lamb, LA
    Quinn, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [6] Temozolomide (TMZ) in combination with pegylated interferon alfa-2b for stage IV metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Spieth, K.
    Dummer, R.
    Leiter, U.
    Garbe, C.
    Gille, J.
    Becker, J. C.
    Hauschild, A.
    Tilgen, W.
    Kaufmann, R.
    Schadendorf, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 457S - 457S
  • [7] Phase II trial of extended-dosing temozolomide in patients with melanoma.
    Rietschel, P.
    Ejadi, S.
    Wolchok, J.
    Krown, S.
    Gerst, S.
    Jungbluth, A. A.
    Busam, K.
    Smith, K.
    Panageas, K.
    Chapman, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
  • [8] Phase II study of the frontline combination of ipilimumab and temozolomide in patients with metastatic melanoma.
    Patel, Sapna Pradyuman
    Hwu, Wen-Jen
    Kim, Kevin B.
    Papadopoulos, Nicholas E.
    Hwu, Patrick
    Radvanyi, Laszlo George
    Mahoney, Sandy
    Deburr, Tawania L.
    Liu, Ping
    Bedikian, Agop Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.
    Kaufman, Howard
    Wang, Jiafeng
    Curti, Brendan D.
    Clark, Joseph
    Ernstoff, Marc S.
    Silk, Ann
    Mehnert, Janice M.
    Zloza, Andrew
    Shih, Joe
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Phase 2 study of talabostat and cisplatin in stage IV melanoma.
    Uprichard, MJ
    O'Day, SJ
    Pavlick, AC
    Richards, DA
    Frenette, G
    Stephenson, J
    Anthony, S
    Pacciucci, PA
    Vrhovac, V
    Cunningham, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 725S - 725S
12345